SCHEMBL14725967

SCHEMBL14725967

CCOC(=O)c1cc2c(=O)[nH]c(-c3cccc(OC)c3)cn2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 4/20 0.53
CSNK1D P48730 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
TP53 P04637 1/20 0.45
MAPT P10636 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
THRB P10828 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SPR P35270 1/20 0.43
KMT2A Q03164 1/20 0.43
ELANE P08246 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALOX15 P16050 1/20 0.41
FOS P01100 1/20 0.41
JUN P05412 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23112639 0.84 ADORA3 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL29977130 0.84 ADORA3 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL21630557 0.84 ADORA2A (0.43) KDM4EADORA3SPRELANEGLA
SCHEMBL30719194 0.84 ADORA2A (0.43) KDM4EADORA3SPRELANEGLA
SCHEMBL23112293 0.83 TNKS (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL23112623 0.81 GABRA2 (0.47) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL23112525 0.81 PTGER3 (0.45) ADORA3SPRTNKSPARP1TNKS2
SCHEMBL29977670 0.81 PTGER3 (0.45) ADORA3SPRTNKSPARP1TNKS2
SCHEMBL23112708 0.80 TNKS (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL23112429 0.80 TNKS (0.44) ALDH1A1KDM4EHPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A ALDH1A1 2425/4885KDM4E 2475/4885CSNK1D 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.